HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Medulloblastoma is a highly malignant brain tumor that primarily affects the cerebellum, the region responsible for coordinating voluntary movements and maintaining balance. This aggressive cancer originates in the neural progenitor cells of the developing cerebellum and typically manifests in the posterior fossa of the brain. The exact cause of medulloblastoma is not fully understood, but genetic factors and abnormalities are believed to play a significant role in its development. Common symptoms include headaches, nausea, vomiting, and issues with motor coordination. Due to its location and rapid growth, medulloblastoma often leads to increased intracranial pressure, contributing to these symptoms. Diagnosis involves imaging studies such as MRI and CT scans, as well as a biopsy to confirm the presence of cancerous cells. Treatment strategies usually include surgical removal of the tumor, followed by radiation therapy and chemotherapy. The goal is to eradicate cancer cells while minimizing damage to surrounding healthy brain tissue. Prognosis varies based on factors such as age, extent of tumor spread, and the success of treatment. Advances in research have led to a better understanding of the molecular subtypes of medulloblastoma, allowing for more personalized and targeted therapies. While advancements in treatment have improved outcomes, managing medulloblastoma remains a complex challenge. Ongoing research efforts continue to explore novel therapeutic approaches, aiming to enhance the overall survival and quality of life for individuals affected by this aggressive brain tumor.
